Drug Development
Drug pipeline expanded with three preclinical candidates
Published in AIDS Weekly, February 7th, 2005
The three compounds are BL-1030, a small molecule for the treatment of Inflammatory Bowel Disease; BL-1050, a novel HIV therapeutic; and BL-2010, an innovative technology for the treatment of resistant cancer.
The worldwide exclusive license agreements were signed with Rimonyx Pharmaceuticals, Ltd., of Nes Ziona, Israel for the development of BL-1030; Yissum, the technology transfer company of The Hebrew University in Jerusalem for BL-1050, and Ramot at Tel Aviv University, Ltd., the technology transfer company of Tel Aviv...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-02-07)
More Articles from AIDS Weekly
- HIV/AIDS Pathology
Semen volume/sperm motility/normal sperm morphology reduced after HIV infection - HIV/AIDS Therapy
Dual CCR5/CXCR4 antagonist inhibits HIV-1 replication - HIV/AIDS Therapy
N-substituted pyrrole derivatives block HIV fusion - HIV/AIDS Therapy
Polyarginine inhibits gp160 processing by furin and suppresses HIV-1 infection - HIV/AIDS Therapy
d4T with/without 3TC is an alternative to ZDV for HIV-infected pregnant women - Aflatoxin Exposure
Aflatoxin exposure and toxicity add to disease burden in developing countries - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
